PCSK9抑制剂处方支付方批准与拒绝率及成功处方的患者特征
结果显示仅47.0%获支付方批准,商业第三方支付方批准率最低(24.4%),Medicare最高(60.9%);支付方类型是影响批准的最显著因素。
要点
- PCSK9i处方整体支付方批准率仅47.0%。
- 商业第三方支付方批准率最低(24.4%),Medicare最高(60.9%)。
- 支付方类型是批准的最显著影响因素,高于临床特征。
核心结论
- PCSK9i治疗获批率低,即使患者看似符合标签适应证。
- 临床特征组合可提高获批可能性,但支付方类型是最显著因素。
研究设计与样本
- 回顾性描述性队列研究,使用全国药房索赔链接电子病历数据仓库。
主要发现
- 47.0%的PCSK9i处方获支付方覆盖批准。
- 与批准相关的变量包括年龄>65岁(P<0.01)、动脉粥样硬化性心血管疾病史(P<0.01)、由心内科或非初级保健提供者开具(P<0.01)、他汀不耐受(P=0.03)、他汀使用时间更长(P=0.01)及非商业支付方(P<0.01)。
- 更高的低密度脂蛋白胆固醇水平与更高批准率无关。
- 商业第三方支付方批准率最低(24.4%),Medicare最高(60.9%)。
临床怎么用
- 处方PCSK9i时应预判支付方审批障碍,尤其商业保险患者。
- 心内科或非初级保健提供者开具处方与更高获批率相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lipid lowering beyond dietary measures and statin use. Because of the drugs' high cost, rates of prescription approval by payers may be low. We aimed to identify payer approval and rejection rates for PCSK9i prescriptions and the potential factors influencing these rates. METHODS: This is a retrospective, descriptive cohort study using nationwide pharmacy claims linked to electronic medical records from a nationwide data warehouse. The data set includes >220 million patients from all 50 states and all payer types with 5140 distinct health plans. PCSK9i prescriptions were submitted for 51 466 patients in the pharmacy data set. The main outcome was approval or rejection of PCSK9i prescription claims. Factors associated with approval and rejection of these medications in the United States were assessed. RESULTS: Among patients who were prescribed a PCSK9i, 47.0% were approved for coverage by the payer. Variables that were associated with PCSK9i approval included age >65 years (P<0.01), history of atherosclerotic cardiovascular disease (P<0.01), prescription by a cardiologist or nonprimary care provider (P<0.01), statin intolerance (P=0.03), longer statin duration (P=0.01), and noncommercial payers (P<0.01). Higher low-density lipoprotein cholesterol levels were not associated with higher approval rates. Commercial third-party payers had the lowest approval rates (24.4%) and Medicare had the highest (60.9%). CONCLUSIONS: Rates of approval for PCSK9i therapy are low, even for patients who appear to meet labeled indications. Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant factor.
引用
- Hess GP, Natarajan P, Faridi KF, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017. PMID: 29084735. doi:10.1161/CIRCULATIONAHA.117.028430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。